Cisplatin induced peripheral neuropathy is recently recognized as dose-limiting side effect of cisplatin anticancer therapy.
We did physical examination and electrodiagnostic studies of 21 patients with cisplatin chemotherapy to find out the factors related with cisplatin neuropathy and to make a criterias of patients who need electrodiagnostic studies to detect cisplatin neuropathy.
We concluded as follow:
1) Cisplatin neuropathy is mainly sensory axonopathy.
2) Cumulative dosage of cisplatin is the most important factor related with cisplatin neuropathy
3) The patients recieving more than 300㎎/㎡ of cisplatin in cumulative dosage should be done electrodiagnostic studies.
